216 related articles for article (PubMed ID: 18509642)
21. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
[TBL] [Abstract][Full Text] [Related]
22. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
Demma MJ; Mapelli C; Sun A; Bodea S; Ruprecht B; Javaid S; Wiswell D; Muise E; Chen S; Zelina J; Orvieto F; Santoprete A; Altezza S; Tucci F; Escandon E; Hall B; Ray K; Walji A; O'Neil J
Mol Cell Biol; 2019 Nov; 39(22):. PubMed ID: 31501275
[TBL] [Abstract][Full Text] [Related]
23. 3JC48-3 (methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth.
Shukla S; Fletcher S; Chauhan J; Chalfant V; Riveros C; Mackeyev Y; Singh PK; Krishnan S; Osumi T; Balaji KC
Cancer Gene Ther; 2022 Nov; 29(11):1550-1557. PubMed ID: 35440696
[TBL] [Abstract][Full Text] [Related]
24. CDC6 interacts with c-Myc to inhibit E-box-dependent transcription by abrogating c-Myc/Max complex.
Takayama M; Taira T; Iguchi-Ariga SM; Ariga H
FEBS Lett; 2000 Jul; 477(1-2):43-8. PubMed ID: 10899308
[TBL] [Abstract][Full Text] [Related]
25. Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.
Soodgupta D; Pan D; Cui G; Senpan A; Yang X; Lu L; Weilbaecher KN; Prochownik EV; Lanza GM; Tomasson MH
Mol Cancer Ther; 2015 Jun; 14(6):1286-1294. PubMed ID: 25824336
[TBL] [Abstract][Full Text] [Related]
26. Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits.
Vyas AR; Moura MB; Hahm ER; Singh KB; Singh SV
J Cell Biochem; 2016 Nov; 117(11):2482-95. PubMed ID: 26990292
[TBL] [Abstract][Full Text] [Related]
27. Inhibitor of MYC identified in a Kröhnke pyridine library.
Hart JR; Garner AL; Yu J; Ito Y; Sun M; Ueno L; Rhee JK; Baksh MM; Stefan E; Hartl M; Bister K; Vogt PK; Janda KD
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12556-61. PubMed ID: 25114221
[TBL] [Abstract][Full Text] [Related]
28. Targeted Disruption of Myc-Max Oncoprotein Complex by a Small Molecule.
Choi SH; Mahankali M; Lee SJ; Hull M; Petrassi HM; Chatterjee AK; Schultz PG; Jones KA; Shen W
ACS Chem Biol; 2017 Nov; 12(11):2715-2719. PubMed ID: 28976731
[TBL] [Abstract][Full Text] [Related]
29. Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells.
Grinberg AV; Hu CD; Kerppola TK
Mol Cell Biol; 2004 May; 24(10):4294-308. PubMed ID: 15121849
[TBL] [Abstract][Full Text] [Related]
30. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
31. Unsaturated fatty acids bind Myc-Max transcription factor and inhibit Myc-Max-DNA complex formation.
Chung S; Park S; Yang CH
Cancer Lett; 2002 Dec; 188(1-2):153-62. PubMed ID: 12406560
[TBL] [Abstract][Full Text] [Related]
32. Reconstitution of an E box-binding Myc:Max complex with recombinant full-length proteins expressed in Escherichia coli.
Farina A; Faiola F; Martinez E
Protein Expr Purif; 2004 Apr; 34(2):215-22. PubMed ID: 15003254
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent.
Tatsuta N; Suzuki N; Mochizuki T; Koya K; Kawakami M; Shishido T; Motoji N; Kuroiwa H; Shigematsu A; Chen LB
Cancer Chemother Pharmacol; 1999; 43(4):295-301. PubMed ID: 10071980
[TBL] [Abstract][Full Text] [Related]
34. Fatty acids, inhibitors for the DNA binding of c-Myc/Max dimer, suppress proliferation and induce apoptosis of differentiated HL-60 human leukemia cell.
Jung KC; Park CH; Hwang YH; Rhee HS; Lee JH; Kim HK; Yang CH
Leukemia; 2006 Jan; 20(1):122-7. PubMed ID: 16281068
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry.
Harvey SR; Porrini M; Stachl C; MacMillan D; Zinzalla G; Barran PE
J Am Chem Soc; 2012 Nov; 134(47):19384-92. PubMed ID: 23106332
[TBL] [Abstract][Full Text] [Related]
37. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo.
Grandori C; Mac J; Siëbelt F; Ayer DE; Eisenman RN
EMBO J; 1996 Aug; 15(16):4344-57. PubMed ID: 8861962
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer.
Yang J; Ahn S; Wu Z; Hwang DJ; Miller DD; Dalton JT
Int J Oncol; 2012 Jul; 41(1):337-44. PubMed ID: 22576690
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
[TBL] [Abstract][Full Text] [Related]
40. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
